RedHill Biopharma develops medicines for gastrointestinal and infectious diseases, promoting drugs like Talicia for H. pylori infections and Aemcolo for travelers’ diarrhea. Their late-stage programs include RHB-204, opaganib, RHB-107, RHB-104, and RHB-102.
RDHL has been in the news recently: Veeva Systems will hold an R&D and Quality Summit in Madrid on June 4-5, 2025, with over 1,400 biopharma professionals discussing innovations in drug development. Separately, DJS Law Group is notifying investors about a class action lawsuit against Zenas Biopharma for allegedly misleading statements during its IPO.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
